285: The Impact of Socioeconomic Factors on Prostate Cancer Outcomes in a Large Series of African-American Patients

2007 ◽  
Vol 177 (4S) ◽  
pp. 95-95
Author(s):  
Atreya Dash ◽  
Peng Lee ◽  
Qin Zhou ◽  
Aaron D. Berger ◽  
Jerome Jean-Gilles ◽  
...  
2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 41-41
Author(s):  
Daniel Canter ◽  
Julia E. Reid ◽  
Maria Latsis ◽  
Margaret Variano ◽  
Shams Halat ◽  
...  

41 Background: Prostate cancer (PC) is the most common male malignancy. Prior data has suggested that African American (AA) men present with more aggressive disease relative to men of other ancestries. Here, we examined the effects of ancestry on clinical and molecular measures of disease aggressiveness as well as pathologic outcomes in men treated with radical prostatectomy (RP) for localized PC. Methods: Data was collected from patients undergoing RP at the Ochsner Clinic from 2006 to 2011. Formalin−fixed paraffin embedded biopsy tissue was analyzed for the RNA expression of 31 cell cycle progression (CCP) genes and 15 housekeeping genes to obtain a CCP score (a validated molecular measure of PC aggressiveness). Cancer of the Prostate Risk Assessment (CAPRA) scores were also determined based on clinicopathologic features at the time of diagnosis. Clinical (Gleason score, tumor stage, CAPRA score) and molecular (CCP score) measures of disease aggressiveness were compared based on ancestry (AA versus non−AA). Cox proportional hazards models were used to test association of ancestry to biochemical recurrence (BCR) and progression to metastatic disease. Fisher’s exact and Wilcoxon rank sum tests were used to compare ancestries. Results: A total of 384 patients were treated with RP, including 133 (34.8%) AA men. At the time of diagnosis, the median age was 62 years (interquartile range (IQR) 56, 66) and PSA was 5.4 ng/mL (IQR 4.2, 7.6). When compared by ancestry, there were no significant differences in biopsy Gleason score (p = 0.26), clinical stage (p = 0.27), CAPRA score (p = 0.58), or CCP score (p = 0.87). In addition, there was no significant difference in the risk of BCR between ancestries (p = 0.55). Only non−AA men progressed to metastatic disease within the ten years of follow−up. Conclusions: Contrary to prior reports, these data appears to indicate that men of AA ancestry do not necessarily present with or develop a more biologically aggressive form of PC. Although these data represents only one institution’s experience, it contains a highly robust AA population compared to prior reports. Further research is required to account for the discrepancy in the previously published literature.


Urology ◽  
2008 ◽  
Vol 72 (3) ◽  
pp. 641-646 ◽  
Author(s):  
Atreya Dash ◽  
Peng Lee ◽  
Qin Zhou ◽  
Jerome Jean-Gilles ◽  
Samir Taneja ◽  
...  

2016 ◽  
Vol 48 (12) ◽  
pp. 2015-2021 ◽  
Author(s):  
William A. Sterling ◽  
Joseph Weiner ◽  
David Schreiber ◽  
Komal Mehta ◽  
Jeffrey P. Weiss

2012 ◽  
Vol 84 (3) ◽  
pp. S409-S410
Author(s):  
W.F. Mourad ◽  
D. Shasha ◽  
R.A. Shourbaji ◽  
D. Berlach ◽  
D. Boo ◽  
...  

2019 ◽  
Vol 201 (4) ◽  
pp. 742-750 ◽  
Author(s):  
Tyler Etheridge ◽  
Jinn-ing Liou ◽  
Tracy M. Downs ◽  
E. Jason Abel ◽  
David F. Jarrard ◽  
...  

2012 ◽  
Vol 40 (1) ◽  
pp. 11-18 ◽  
Author(s):  
Kushal Patel ◽  
Flora Ukoli ◽  
Jianguo Liu ◽  
Derrick Beech ◽  
Katina Beard ◽  
...  

The purpose of the study was to assess the impact of an educational intervention on prostate cancer screening behavior and knowledge. Participants were 104 African American men, 45 years and older, who had not been screened for prostate cancer with a prostate-specific antigen and/or digital rectal exam within the past year. All participants received an intervention delivered by trained lay community educators using a prostate cancer educational brochure developed in collaboration with the community, with structured interviews preintervention and 3 months postintervention. The main study outcomes included prostate-specific antigen screening rates during the 3-month interval and knowledge, barriers to screenings, and decisional conflict around screening. Compared with the 46 men who did not get screened, the 58 participants who got screened were more likely to have greater than a high school education, annual household incomes ≥$25,000, and a family history of non–prostate cancer ( p < .05). Average knowledge scores increased, and barriers to screening scores decreased, from preintervention to postintervention only for participants who had been screened ( p < .05). The results of this study demonstrate the feasibility and efficacy of an academic institution collaborating with the African American community to develop a successful prostate cancer educational intervention, an approach that can be expanded to other cancers and other chronic diseases.


2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4555-4555
Author(s):  
Sarah Maria Rudman ◽  
Kathryn P. Gray ◽  
Julie Kasperzyk ◽  
Edward Giovannucci ◽  
Michael Pitt ◽  
...  

4555 Background: The metabolic syndrome (MS) has been implicated in the development of prostate cancer (PC). In our previous study of a Veterans’ Administration (VA) cohort, MS was associated with a shorter duration of PC control with ADT. We report the impact of MS on overall survival (OS) and PC specific death for a cohort of patients with biochemical relapse. Methods: 273 pts (64 VA pts and 209 pts from Health Professionals Follow up Study) treated with ADT for biochemical recurrence post radiation or prostatectomy for PC were included. The modified Adult Treatment Panel III criteria for MS was used to identify patients with MS status prior to the commencement of ADT. Cox models tested for association of MS status with OS or time to PC specific death. With 42% overall death rate, 31% MS prevalence, there was 90% power to detect HR= 1.81 (type I error rate =0.05). Results: 31% pts (84/273) had MS and 15% pts (40/273) died of PC. Median follow-up was 9.5 years. The median OS with and without MS was 7.4 and 11.2 years respectively. Patients with hypertension, being African American, having diabetes and age were associated with increased risk of death from any causes, while hypertension and being African American were also associated with increased risk of PC specific death. A multivariate Cox regression model adjusted for age at diagnosis, race, definitive local therapy (RT vs. RP), PSA at diagnosis and Gleason score revealed MS was associated with a significantly increased risk of death from any cause and PC specific death (Table). Conclusions: In men receiving ADT for biochemically recurrent androgen dependent PC, the presence of MS at the commencement of ADT is associated with an increased risk of death from any cause as well as prostate cancer specifically. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document